Helga Fibiger Munch‐Petersen

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Konstantinos Dimopoulos, Alexandra S. Helbo, Helga Fibiger Munch‐Petersen et al. · Molecular Oncology · 2017 · 83 citations · Full text

Hematological Malignancy, Tumor Biology, Dual Inhibition +14

Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets

Nicolai Krogh, Fazila Asmar, Christophé Côme et al. · NAR Cancer · 2020 · 50 citations · Full text

Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging

Florian P.Y. Barré, Britt S. R. Claes, Frédéric Dewez et al. · Analytical Chemistry · 2018 · 43 citations · Full text

Vivo Imaging, Immunology, Biological Mass Spectrometry +18

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

Konstantinos Dimopoulos, Helga Fibiger Munch‐Petersen, Christian Winther Eskelund et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 28 citations

Cereblon Pathway, Mixed-phenotype Acute Leukemia, Immunology +17

Constitutional <i>POLE</i> variants causing a phenotype reminiscent of constitutional mismatch repair deficiency

Astrid Sehested, Julia Meade, David Scheie et al. · Human Mutation · 2021 · 21 citations · Full text